diarrhea, and non-specific physical signs including hepatosplenomegaly and diffuse lymphadenopathy. Clinicians have utilized serologic markers of EBV infection to assist in the diagnosis; however, seroconversion may not occur in up to 37% of pediatric patients with PTLD (1) . More recently, the use of peripheral blood PCR monitoring of EBV DNA has been shown to be a sensitive and specific method of identifying children at increased risk of developing PTLD (3) . While early reports using RQ-PCR in serum, suggested that PCR was 100% sensitive and 100% specific for the detection of PTLD in children with >1000 copies of EBV per 100 lL plasma, recent studies have suggestive that monitoring is relatively less sensitive but remains fairly specific (4, 5) . Similarly, significantly elevated viral loads were found in 10 of 10 patients with known PTLD using a TaqMan based EBV-PCR assay (6) .
EBV-PCR in PBLs has been widely applied clinically in our institution and is used as an initial diagnostic evaluation in patients with suspected EBV induced PTLD (7) . However, in this report, we described two patients with pathologically proven PTLD associated with EBV who had no sustained elevation in virus detected using PCR above 100 copies per 10 Abstract: Post-transplant lymphoproliferative disorder (PTLD) represents a significant threat to the survival of pediatric transplant recipients. Epstein-Barr (EBV) viral load monitoring using polymerase chain reaction (PCR) has been reported to have a variable sensitively with relatively higher specificity as in an indicator of the development of PTLD. We report two cases of pathologically confirmed PTLD in children who failed to develop sustained increases in their EBV-PCR determined viral loads. We suggest that clinicians should be aware of the potential for false-negative results of EBV-PCR in pediatric transplant recipients. 
Results

Case report 1
AA was the product of a 32 wk twin gestation who was born at 2.2 kg. Shortly after birth, AA presented to her primary care physicians with fussiness and irritability. Laboratory studies obtained as part of an evaluation for sepsis revealed a total protein of 2.8 g/dL and an albumin of 1.0 g/dL. AA was subsequently diagnosed with congenital nephrotic syndrome. AA was managed with dietary supplementation and i.v. albumin until 6 months of age. At this time, AA underwent bilateral nephrectomy to prevent ongoing proteinuria. AA was managed on hemodialysis for 22 days and subsequently underwent a living related renal transplant from her mother in 1993 at the University of Michigan Medical Center. AA was CMV sero-negative and EBV sero-negative and received a CMV positive organ. AA received ATGAM induction and her initial immunosuppression included prednisone, cyclosporine, and azathioprine. AA did well after transplant aside from reflux at her ureteroneocystostomy requiring collagen injections and re-implantation. AA developed a rising creatinine 36 months post-transplant. Graft biopsy was consistent with chronic cyclosporine toxicity and her immunosuppression was changed from azathioprine to MMF.
AA's clinical course remained stable until 90 months after transplantation during this which time AA was treated with growth hormone for 30 months for short stature. AA then presented with fever to 103°F. AA was initially treated for bronchitis at an outside hospital and discharged with persistent, intermittent fevers. AA subsequently presented to the University of Michigan with fevers to 105°and an elevated creatinine. No source for her fever was identified. A renal biopsy revealed chronic cyclosporine toxicity and evidence of acute tubular necrosis.
Her cyclosporine dosed was reduced. Additionally, serologic studies for CMV were negative. An EBV-PCR was also obtained, and no virus was detectable in the patient's peripheral lymphocytes (Table 1 Following diagnosis, MMF and Cyclosporine were withdrawn and chemotherapy initiated. AA was treated with six cycles of COPP/ABV (cytoxan, prednisone, vincristine, procarbazine, velban, bleomycin, and adriamycin). Four months after the initiation of therapy, CT scan revealed no evidence of recurrent disease. Cyclosporine was restarted 8 months following diagnosis. At the time of her most recent follow-up, AA is now 8 yr post-transplant and 15 months after her diagnosis of PTLD. AA is without evidence of recurrence of her Hodgkin's lymphoma and her creatinine is 1.2 mg/dL.
Case Report 2
BB was referred for liver transplant evaluation at age seven. BB was diagnosed with biliary atresia in childhood and underwent a Kasai procedure at 2 months of age. At the time of his transplant evaluation, BB had experienced several episodes of gastrointestinal bleeding as a result of his significant esophageal varicies and splenomegaly. Prior to transplant, BB was EBV sero-negative and CMV sero-negative. BB underwent orthotopic liver transplantation 3 months after evaluation with placement of an endobiliary stent. The donor was a CMV sero-negative, EBV sero-positive 3 yr old. BB was started on tacrolimus, MMF, and prednisone. His post-operative course was uneventful and BB was discharged on post-operative day number five receiving viral prophylaxis with acyclovir. BB received a single dose pulse of steroids for a presumed rejection as a result of rising liver function tests, which was not confirmed by graft biopsy. The patient was re-admitted 6 wk after transplantation with fever to 102.5°following removal of his endobilliary stent. The blood, urine and sputum cultures were obtained, but no pathologic organisms were isolated by laboratory culture. His liver function tests were unremarkable and BB was clinically asymptomatic. BB was subsequently discharged with low-grade fevers. EBV-PCR demonstrated 8 copies per 10 5 lymphocytes (Table 2) . Following his discharge, the patient complained of recurrent low-grade fevers and abdominal pain. Physical examination revealed tonsillar enlargement. Given these findings, a repeat EBV-PCR was obtained and there was a transient rise in his titers from 8 to 100 copies. An abdominal-pelvic CT was obtained which demonstrated a small hypodense lesion in the left lobe of the liver and multiple small areas in the parenchyma of the right kidney showing no enhancement that were suspicious but not diagnostic for PTLD. The immunosuppression was not altered given the results of the EBV-PCR. Both the CT scan and the EBV-PCR were subsequently repeated within 1 month. These repeat studies demonstrated a reduction in viral load to 40 genomes per 10 5 lymphocytes and no visible lesions on CT.
BB did well for an additional 2 months when BB developed nausea, vomiting and weight loss. BB was evaluated with EGD and colonoscopy that were normal. BB was also noted to have persistent tonsillar enlargement, and underwent tonsillectomy. Pathologic examination revealed no PTLD. Three weeks following tonsillectomy, BB represented with decreased oral intake, weight loss, and repeat CT scan demonstrated irregular thickening of several small intestinal loops in the right lower quadrant consistent with PTLD. Repeat EBV-PCR revealed only 80 genomes per 10 5 lymphocytes. The patient was then taken for exploratory laparoscopy 1 wk later, which was converted, to open laparotomy. At operation, a large right lower quadrant mass involving 12 cm of distal ilium was resected. BB was also found to have massive mesenteric adenopathy. Pathologic examination of this mass demonstrated a diffuse large B-cell lymphoma (monomorphic PTLD). Numerous cells were positive for EBV-LMP as well as CD20. PET scanning obtained post-operatively demonstrating 11 foci of abnormally increased FDG uptake in the mid abdomen, corresponding to lymph nodes involved with his neoplasm.
Following his diagnosis, the patient's immunosuppression was withdrawn and was treated with four doses of Rituximab. Six weeks following diagnosis and withdrawal of his immunosuppression, BB had rising liver function tests. BB was biopsied and treated for acute cellular rejection. Despite initial improvement with pulse steroids, the patient's liver function has continued to worsen. Subsequent biopsy has demonstrated chronic rejection, and BB is now being considered for retransplantation. Following completion of therapy with Rituximab and six cycles of cytoxan, the patient's CT scan demonstrated complete regression of his tumor. Repeat PET scan demonstrated no active disease.
Discussion
The development of PTLD represents one of the most lethal complications of solid organ transplantation. The incidence of PTLD varies by organ and has been reported in 2.6-9.0% of pediatric renal transplant recipients (8) (9) (10) (11) with malignancy developing in 1.5%. Among liver recipients, PTLD has been diagnosed in 6.8-13.1% of recipients (12, 13) . Furthermore, the incidence of PTLD appears to be increasing in pediatric renal transplant recipients from 298 to 395 cases per 100 000 yr of patient follow-up (13) .
Detection of PTLD requires a high index of suspicion, particularly among patients with known risk factors including: younger age at transplant, EBV negative recipients transplanted 8 with an EBV positive organ, CMV infection, OKT3 treatment, and, possibly, tacrolimus based immunosuppression. In patients suspected of having PTLD, an aggressive diagnostic evaluation with radiographic imagining and serologic evaluation is indicated as early diagnosis may be correlated with better outcome (14) . Histologic evaluation of an appropriate biopsy specimen is necessary to differentiate PTLD from acute cellular rejection, which often has a similar presentation. Given the difficulty in identifying PTLD, viral load monitoring has been a very useful addition to the diagnostic techniques. Elevated levels of EBV DNA have been correlated with PTLD in several non-quantitative assays. The presence of low levels of EBV viral DNA is not uncommon in the immunosuppressed population, and has been documented in up to 19% of healthy solid organ transplant recipients (6) . The development of a quantitative PCR technique has significantly improved the specificity for PTLD and may serve as an early marker in high-risk patients. Quantitative PCR as originally described by Rowe and colleagues utilized a competitive PCR assay in which viral load was quantified by co-amplifying varying quantities of a competitor plasmid under identical conditions (3) . Using this assay, 13 of 14 patients with PTLD had >500 copies per 10 5 lymphocytes. The resulting sensitivity was reported as 92.8% and the specificity was 100% (3).
PCR has also been effectively used to monitor high risk transplant patients and identify those with an increase risk for PTLD (15) . Frequent monitoring and treatment with reduction of immunosuppression and anti-viral therapy has been reported to reduce the incidence of PTLD in pediatric liver transplant patients from 10 to 5% when compared with historical controls (16) . Similarly in children undergoing small bowel transplant, the use of frequent monitoring has resulted in a reduction in the incidence of PTLD from 40 to 11% (17) . EBV-PCR monitoring has also proven to be a useful strategy following the treatment of PTLD. Response to therapy is correlated with a decrease in viral load to <200 copies per 10 5 cells (18) . This reduction is reflective of an effective immune response against EBV-infected B-cells and is an early predictor of clinical outcome (15) . Persistence of viral loads less than this level appears to signal that re-introduction of low dose immunosuppression is safe.
While EBV-PCR clearly has a role in the clinical management of the post-transplant patient, several limitations have been recognized. First, as shown by the patients included in this report, quantitative EBV-PCR may fail to identify patients with PTLD whose viral loads fail to meet an identified threshold value. Green and colleagues described a similar child in whom PTLD with nervous system involvement was diagnosed in a patient who had a past history of systemic PTLD. This child was noted to have a low EBV load by PCR despite active disease. Second, there may be an overlap in viral levels in patients with PTLD and EBVassociated viral syndromes (19) . Finally, the significance of viral levels in the post-PTLD patient remains unclear. Patients may have a rebound in their viral load following the re-introduction of immunosuppression. However, the vast majority will not develop recurrent disease (15) .
It is not clear why EBV-PCR monitoring failed to identify the development of PTLD in our patients. In patient AA, the late development (91 months post-transplant) of Hodgkin's disease, an uncommon histologic subtype may be responsible. While late onset PTLD has been associated with a higher incidence of EBV negative tumors, this was not the case in this patient as her tumor was proven to be EBV positive (2) . The second patient had recently received acyclovir, which may have artificially suppressed his viral load. However, the bulk of the viral load in peripheral blood in patients with PTLD is believed to be related to immortalized cells and not lytic infection [which is suppressed by anti-viral agents (19) ] Furthermore, EBV viral loads may climb, even in the face of i.v. acyclovir or gancilovir (16) . Thus, it appears unlikely that the acyclovir therapy is primarily responsible for the low levels of EBV documented in this case. Hopefully, the availability of rapid, accurate viral load monitoring will facilitate further research to understand the pathologic basis of PTLD in patients who do not manifest high viral loads.
In summary, we report two cases of PTLD in patients with very low viral loads. Each patient was high risk for PTLD based on his or her initial EBV serology. While our clinical suspicion remained high, the resulting low EBV-PCR may have provided a false sense of re-assurance. In both instances, the use of CT technology was diagnostic once lesions of sufficient size had developed. While EBV-PCR remains a useful screening test in patients who are at high risk for PTLD, a significant minority of patients may have active disease despite low viral loads and alternative diagnostic modalities should be utilized to insure an early, accurate diagnosis.
